250+ hematology sitesaround the world
The global leader in hemophilia & hematology studies
More than 50% of operational staff has hematology/oncohematology experience.
Excellent working relationships with KOLs globally
Current knowledge of enrollment rates and global competition
PSI’s key differentiator is our ability to plan and execute complex clinical trials on time, saving our customers millions of development dollars.
- Several dozen studies successfully completed across 40 countries
- Currently working with 250+ oncohematology sites worldwide
- Thousands of sites in North America, Latin America, Europe, and Asia Pacific
- Aced FDA inspections to PSI sites
Contributed to several drug approvals in: Multiple Myeloma, Lymphoma and other related indications.
“Thanks again to all the PSI teams that helped us in completing enrollment in our pivotal Phase III trials -- safe to say we could have never done it without PSI.” VP, Clinical Operations and Data Management